GlassScriptPhysician profile
Lawrence C Antonucci
NPI 1083684914
$6,590.92
in general payments reported to CMS, 2019-2025
31 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $900 · 2021: $1,620 · 2022: $828 · 2023: $693 · 2024: $1,098 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.18 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,234.22 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $628.41 | 2020-2025 | |
| Esperion Therapeutics, INC. | $591.95 | 2020-2024 | Nexletol |
| Amgen INC. | $572.51 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $570.14 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $558.98 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $460.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $354.91 | 2019-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $289.58 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $235.34 | 2020-2025 | Farxiga, Lokelma |
| Pfizer INC. | $207.02 | 2020-2025 | |
| Amarin Pharma, INC. | $206.70 | 2021-2023 | |
| Boston Scientific Corporation | $155.26 | 2020-2024 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $86.76 | 2019-2022 | |
| Heartflow, INC. | $68.39 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $43.50 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $40.23 | 2021 | |
| Biosense Webster, INC. | $37.80 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.38 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $32.49 | 2024 | Arcalyst |
| Altathera Pharmaceuticals LLC | $28.76 | 2022 | |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Bard Peripheral Vascular, INC. | $18.06 | 2019 | |
| Smith+Nephew, INC. | $16.50 | 2024 | Collagenase Santyl |
| United Therapeutics Corporation | $15.35 | 2023 | Tyvaso |
| Amryt Pharma Holdings LTD | $14.77 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.59 | 2023 | Inpefa |
| Chiesi USA, INC. | $14.39 | 2019 | |
| Lundbeck LLC | $12.65 | 2020 | |
| Misonix INC | $12.53 | 2021 | |
| Eisai INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Antonucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.